Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia

References

• Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”?. Hepatology 2001; 34: 194–203
   PubMed Web of Science ®Google Scholar
• Chevrier M C, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, et al. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion 2007; 47: 1794–1802
   PubMed Web of Science ®Google Scholar
• Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47: 1197–1205
   PubMed Web of Science ®Google Scholar
• Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts J P, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142–146
   PubMed Web of Science ®Google Scholar
• Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004; 10: 356–362
   PubMed Web of Science ®Google Scholar
• Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326–1330
   PubMed Web of Science ®Google Scholar
• Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146: 649–656
   PubMed Web of Science ®Google Scholar
• Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando M E, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22–26
   PubMed Web of Science ®Google Scholar
• Kao J H, Chen P J, Lai M Y, Chen D S. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068–4071
   PubMed Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699–712
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 1996; 78: 2210–2215
   PubMed Web of Science ®Google Scholar
• Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67: 45–50
   PubMed Web of Science ®Google Scholar
• Yagci M, Acar K, Sucak G T, Aki Z, Bozdayi G, Haznedar R. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608–1612
   PubMed Web of Science ®Google Scholar
• Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189–191
   PubMedGoogle Scholar
• Niscola P, Del Principe M I, Maurillo L, Venditti A, Buccisano F, Piccioni D, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 1840–841
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Trapani R, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 254–258
   PubMed Web of Science ®Google Scholar
• Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397–408
   PubMedGoogle Scholar
• Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554–557
   PubMed Web of Science ®Google Scholar
• Wang F, Xu R H, Han B, Shi Y X, Luo H Y, Jiang W Q, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007; 109: 1360–1364
   PubMed Web of Science ®Google Scholar
• Chen M H, Hsiao L T, Chiou T J, Liu J H, Gau J P, Teng H W, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2008; 87: 475–480
   PubMed Web of Science ®Google Scholar
• Laskus T, Radkowski M, Wang L F, Nowicki M, Rakela J. Detection and sequence analysis of hepatitis B virus integration in peripheral blood mononuclear cells. J Virol 1999; 73: 1235–1238
   PubMed Web of Science ®Google Scholar
• Murakami Y, Minami M, Daimon Y, Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004; 72: 203–214
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, Deambrogi C, Rossi F M, Zucchetto A, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008; 142: 202–215
   PubMed Web of Science ®Google Scholar
• Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102–110
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Rossi D, De Paoli L, Rossi F M, Cerri M, Deambrogi C, Rasi S, et al. Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. Br J Haematol 2008; 141: 734–736
   PubMed Web of Science ®Google Scholar
• Yoffe B, Noonan C A, Melnick J L, Hollinger F B. Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA. J Infect Dis 1986; 153: 471–477
   PubMed Web of Science ®Google Scholar
• Michalak T I, Pardoe I U, Coffin C S, Churchill N D, Freake D S, Smith P, et al. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999; 29: 928–938
   PubMed Web of Science ®Google Scholar
• Michalak T I, Mulrooney P M, Coffin C S. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 2004; 78: 1730–1738
   PubMed Web of Science ®Google Scholar
• Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int 1995; 48: 1967–1971
   PubMed Web of Science ®Google Scholar
• Lanford R E, Michaels M G, Chavez D, Brasky K, Fung J, Starzl T E. Persistence of extrahepatic hepatitis B virus DNA in the absence of detectable hepatic replication in patients with baboon liver transplants. J Med Virol 1995; 46: 207–212
   PubMed Web of Science ®Google Scholar
• Baginski I, Chemin I, Bouffard P, Hantz O, Trepo C. Detection of polyadenylated RNA in hepatitis B virus-infected peripheral blood mononuclear cells by polymerase chain reaction. J Infect Dis 1991; 163: 996–1000
   PubMed Web of Science ®Google Scholar
• Umeda M, Marusawa H, Seno H, Katsurada A, Nabeshima M, Egawa H, et al. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol 2005; 42: 806–812
   PubMed Web of Science ®Google Scholar
• Ciesek S, Helfritz F A, Lehmann U, Becker T, Strassburg C P, Neipp M, et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis 2008; 197: 355–360
   PubMed Web of Science ®Google Scholar
• Do S. The natural history of hepatitis B in Asian Americans. Asian Am Pac Isl J Health 2001; 9: 141–153
   PubMedGoogle Scholar
• Dighiero G, Hamblin T J. Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017–1029
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yuh K, Sugyo S, Shijo H, Kimura N, Okumura M. Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Gastroenterology 1996; 111: 156–164
   PubMed Web of Science ®Google Scholar
• Ji W, Wang H F, Feng C Q. Activation-induced cell death in peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B may be related to abnormal production of interleukin 12 and 10. J Viral Hepat 2001; 8: 30–33
   PubMed Web of Science ®Google Scholar
• Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection?. Lancet 2005; 365: 638–640
   PubMed Web of Science ®Google Scholar